REG - Futura Medical PLC - Positive Regulatory Update on Pain Portfolio <Origin Href="QuoteRef">FUM.L</Origin>

Futura MedicalAnnouncement

24/11/2015 07:01

RNS Number : 6813G
Futura Medical PLC
24 November 2015
For immediate release 
24 November 2015
Futura Medical plc
("Futura" or the "Company")
Positive Regulatory Update on Pain Portfolio
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that, following a positive meeting with a key European regulator,the Company has received clarity on the regulatory pathways for its topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen). Most significantly, Futura has been advised by the regulator that in principle no further clinical efficacy studies are expected to be required for either of the products prior to the submission of regulatory dossiers in Europe. 
The two products are based on non-steroidal anti-inflammatory drugs (NSAIDs) and benefit fromFutura's transdermal delivery system, DermaSyS, which offers enhanced drug permeation through the skin. TPR100 uses the NSAID diclofenac and TIB200 uses the NSAID ibuprofen. In July this year, Futura announced positive results for the two products, which both showed statistically significant pain relief in a pivotal clinical study.
Futura has been developing the positioning and packaging of the products using the strapline, "DermaSys: Get to the Point with Pain". Prototype product packs can be viewed at this link:
http://www.futuramedical.com/archive/DermaSys-prototype-pack.pdf 
It is expected that Futura will utilise Europe's decentralised regulatory process to gain Marketing Authorisations in all key EU markets. The over the counter (OTC) topical pain relief market in the top five EU countries was worth over US$750 million in 20141.
The Company is also preparing for a formal meeting with the FDA to establish the US regulatory pathway for the two products, although topical NSAIDs are only currently available with a doctor's prescription in the USA. The topical NSAID market in the USA, where a prescription is required, is was worth US$625 million in 20141.
James Barder, Futura's Chief Executive, commented: "We are very pleased to have received such encouraging guidance on the regulatory pathway in Europe for these two novel, DermaSys-based pain relief products. We can now focus on the preparation of our regulatory submissions in Europe and on the regulatory pathway for these innovative products in the USA."
1. Source: IMS data
For further information please contact:
Futura Medical plc

James Barder, Chief Executive
Tel: +44 (0) 1483 685 670
Email to: james.barder@futuramedical.com
www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Liz Yong / Tom Smale
Corporate Finance 
Tel:+44 (0) 20 7496 3000
For media enquiries please contact: 

Buchanan 

Mark Court / Sophie Cowles / Stephanie Watson
Tel: +44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCPKNDDOBDDBDB